{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:55:40Z","timestamp":1789498540747,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Psychiatry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/s2215-0366(23)00288-2","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T03:29:04Z","timestamp":1698895744000},"page":"934-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria"],"prefix":"10.1016","volume":"10","author":[{"given":"John M","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Harary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Eshet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Tohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avia","family":"Merenlender-Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Glen L","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2215-0366(23)00288-2_bib1","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P&T"},{"key":"10.1016\/S2215-0366(23)00288-2_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/S2215-0366(23)00288-2_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319870033","article-title":"Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia","volume":"9","author":"Taylor","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/S2215-0366(23)00288-2_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib7","first-page":"1349","article-title":"Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia","volume":"22","author":"MacEwan","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/S2215-0366(23)00288-2_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/PPA.S127623","article-title":"Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic","volume":"11","author":"Pilon","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/S2215-0366(23)00288-2_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/S2215-0366(23)00288-2_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2658","article-title":"Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate","volume":"33","author":"Girardi","year":"2018","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/S2215-0366(23)00288-2_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/eip.12868","article-title":"Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia","volume":"14","author":"Brown","year":"2020","journal-title":"Early Interv Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14656566.2016.1174692","article-title":"Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia","volume":"17","author":"Hargarter","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/S2215-0366(23)00288-2_bib17","first-page":"36","article-title":"The effects of paliperidone palmitate 1 month on the employment status and social functioning of patients with schizophrenia","volume":"17","author":"Ohnishi","year":"2020","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/S2215-0366(23)00288-2_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","article-title":"Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders","volume":"6","author":"Phahladira","year":"2020","journal-title":"NPJ Schizophr"},{"key":"10.1016\/S2215-0366(23)00288-2_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","article-title":"Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study","volume":"28","author":"Emsley","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 3","key":"10.1016\/S2215-0366(23)00288-2_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","article-title":"Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"36","author":"Nasser","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S2215-0366(23)00288-2_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib23","series-title":"Package Insert","year":"2021"},{"key":"10.1016\/S2215-0366(23)00288-2_bib24","series-title":"Package Insert","year":"2022"},{"key":"10.1016\/S2215-0366(23)00288-2_bib25","series-title":"Package Insert","year":"2023"},{"key":"10.1016\/S2215-0366(23)00288-2_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/PPA.S187120","article-title":"Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18\u201345 years old","volume":"13","author":"Gandell","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/S2215-0366(23)00288-2_bib27","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.4088\/JCP.13024tx3c","article-title":"Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence","volume":"75","author":"Correll","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib28","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.IN18031AH1C","article-title":"Optimizing treatment choices to improve adherence and outcomes in schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S2215-0366(23)00288-2_bib29","doi-asserted-by":"crossref","unstructured":"Perlstein I, Merenlender-Wagner A, Lamson M, et al. Population pharmacokinetic modeling and simulation to guide dose selection for TV-46000, a new long acting formulation of risperidone for subcutaneous injection. American Society for Clinical Pathology 2021 Annual Meeting; October 27\u201329, 2021; Boston, MA.","DOI":"10.1016\/j.euroneuro.2021.10.434"},{"key":"10.1016\/S2215-0366(23)00288-2_bib30","series-title":"Package insert","year":"2023"},{"key":"10.1016\/S2215-0366(23)00288-2_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J Clin Psychiatry"}],"container-title":["The Lancet Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036623002882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036623002882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:21:17Z","timestamp":1762410077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215036623002882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2215036623002882"],"URL":"https:\/\/doi.org\/10.1016\/s2215-0366(23)00288-2","relation":{},"ISSN":["2215-0366"],"issn-type":[{"value":"2215-0366","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria","name":"articletitle","label":"Article Title"},{"value":"The Lancet Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(23)00288-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(23)00309-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}